Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
DR. NOAH BIOTECH INC. has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This 1 pending office action is currently limited to 1 distinct examiner and 1 distinct art unit, which indicates a highly specialized and concentrated effort. In the Biotechnology & Pharmaceuticals technology area, having 1 pending office action allows the practitioner to focus deeply on the specific scientific and legal challenges presented by 1 distinct art unit. This focus is essential for navigating the rigorous examination standards typically found in this field of technology.
The busiest examiner for this portfolio is ANDERSON, REBECCA L, who is responsible for 1 busiest examiner pending action. Because this 1 busiest examiner pending action represents the entirety of the company's pending workload, the interaction with ANDERSON, REBECCA L is the most critical element of their current prosecution strategy. Practitioners should analyze the 1 distinct examiner's previous rulings and preferences to better anticipate the requirements for success. The concentration in 1 distinct art unit further suggests that the company's current research and development focus is tightly aligned with a specific technological niche in Biotechnology & Pharmaceuticals.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ANDERSON, REBECCA L | 1 | 73.3% | +23.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18278166 | COMPOSITION COMPRISING BETA BLOCKER AND CHOLINESTERASE INHIBITOR FOR TREATMENT OF NEURODEGENERATIVE DISEASE | ANDERSON, REBECCA L | — |
| Art Unit | Apps |
|---|---|
| 1626 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18278166 | COMPOSITION COMPRISING BETA BLOCKER AND CHOLINESTERASE INHIBITOR FOR TREATMENT OF NEURODEGENERATIVE DISEASE | ANDERSON, REBECCA L | 1626 | §103 | Final Rejection | — | Pending | Aug 21, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialDR. NOAH BIOTECH INC. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Rebecca L Anderson has the most, with 1 of DR. NOAH BIOTECH INC.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
